[Skip to Content]
[Skip to Content Landing]
April 14, 1956


JAMA. 1956;160(15):1320-1321. doi:10.1001/jama.1956.02960500050014

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In recent months, considerable interest has been generated in medical circles concerning certain new sulfonamide compounds that are reported to lower the blood sugar level and to reduce glycosuria in certain diabetic patients after oral administration. Unfortunately, it has resulted in widespread publicity in the lay press. Although one of these compounds, 1-butyl-3-sulfanilylurea, designated carbutamide, has been administered to about 3,500 patients with diabetes in Germany in the past three years and to several hundred diabetics in the United States, it is still too early to predict its possible future role in the treatment of this disease. On page 1285 of this issue of The Journal is a preliminary report on the use of this compound in 18 patients with diabetes. At least one other drug within this chemical family is under trial on a large scale in the United States. It is the purpose of this editorial to summarize

First Page Preview View Large
First page PDF preview
First page PDF preview